CVRx (NASDAQ:CVRX) Posts Earnings Results, Misses Estimates By $0.02 EPS

CVRx (NASDAQ:CVRX) announced its quarterly earnings results on Thursday. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.02), FiscalAI reports. The firm had revenue of $13.83 million during the quarter, compared to the consensus estimate of $13.93 million. CVRx had a negative net margin of 84.93% and a negative return on equity of 152.35%.

Here are the key takeaways from CVRx’s conference call:

• CVRx lowered its 2026 revenue outlook to $56 million–$57 million from $58 million–$60 million, after Q3 revenue fell 6.1% year over year to $13.8 million. Q4 revenue is expected to be $11.7 million–$12.7 million.
• Reimbursement delays at UnitedHealthcare, CVRx’s largest Medicare Advantage payer, were a major drag: the 30-day approval rate for cases handled by the company fell to about 12% from a 2025 high of 83%. CVRx is appealing denials, but says the process can take months and many customer-handled denials may not be appealed.
• Physician-champion turnover and uneven sales-team experience are slowing adoption; four of nine U.S. regions are struggling to match the growth of the five more tenured regions. Management cited early improvement in team stability but said the recovery will take time.
• CVRx reported progress in coverage and clinical evidence: two written Medicare Advantage policies now cover a combined 21% of those lives, and traditional Medicare claims data showed all submitted Q1 2026 claims were paid. In the REBALANCE real-world study, the indicated-patient group had sustained functional-class improvements and improved ejection fraction through 24 months.
• CVRx ended Q3 with $58.7 million in cash and said it has at least 18 months of runway, excluding potential additional ATM proceeds. It expects 2026 operating expenses of $99 million–$101 million after cost reductions, while continuing to invest in sales and reimbursement.

CVRx Stock Performance

Shares of CVRX traded down $0.64 during trading hours on Friday, hitting $0.83. The stock had a trading volume of 3,828,297 shares, compared to its average volume of 528,661. The stock has a fifty day moving average price of $2.13 and a 200 day moving average price of $5.18. CVRx has a 12 month low of $0.77 and a 12 month high of $10.28. The company has a debt-to-equity ratio of 2.94, a current ratio of 8.04 and a quick ratio of 6.87. The firm has a market capitalization of $22.06 million, a PE ratio of -0.42 and a beta of 0.81.

Insider Buying and Selling

In other CVRx news, COO Brent Binkowski purchased 26,223 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was acquired at an average cost of $2.91 per share, for a total transaction of $76,308.93. Following the purchase, the chief operating officer directly owned 56,514 shares of the company’s stock, valued at $164,455.74. This trade represents a 86.57% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 16.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on CVRX. Craig Hallum downgraded shares of CVRx from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a report on Friday, August 7th. Canaccord Genuity Group lowered shares of CVRx from a “buy” rating to a “hold” rating and set a $2.00 target price for the company. in a research report on Friday. Lake Street Capital downgraded shares of CVRx from a “buy” rating to a “hold” rating and lowered their price target for the stock from $14.00 to $3.50 in a report on Friday, August 7th. Piper Sandler lowered CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 price objective for the company. in a report on Friday, August 7th. Finally, Cantor Fitzgerald reduced their price objective on CVRx from $13.00 to $5.00 and set an “overweight” rating on the stock in a research report on Monday, August 17th. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, CVRx currently has a consensus rating of “Hold” and a consensus target price of $3.70.

CVRx Company Profile

CVRx, Inc (NASDAQ: CVRX) is a medical device company focused on developing and commercializing neuromodulation therapies for patients with cardiovascular diseases. The company’s technology is designed to activate the body’s natural nervous system pathways to help regulate cardiovascular function.

CVRx’s primary product is the Barostim system, an implantable device that delivers electrical stimulation to baroreceptors located near the carotid arteries. By influencing signals between the cardiovascular system and the brain, Barostim is intended to reduce excessive sympathetic nervous system activity and improve symptoms and function in certain patients with heart failure.